BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20934265)

  • 21. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
    Glynne-Jones R; Meadows H; Wan S; Gollins S; Leslie M; Levine E; McDonald AC; Myint S; Samuel L; Sebag-Montefiore D;
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):119-26. PubMed ID: 18472366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
    Northover J; Glynne-Jones R; Sebag-Montefiore D; James R; Meadows H; Wan S; Jitlal M; Ledermann J
    Br J Cancer; 2010 Mar; 102(7):1123-8. PubMed ID: 20354531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients].
    Grabenbauer GG; Panzer M; Hültenschmidt B; Döker R; Huber K; Kuhne-Velte HJ; Hutter M; Rühl U; Budach V; Wendt T
    Strahlenther Onkol; 1994 Jul; 170(7):391-9. PubMed ID: 8052938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effect of the UK Coordinating Centre for Cancer Research Anal Cancer Trial (ACT1) on Population-based Treatment and Survival for Squamous Cell Cancer of the Anus.
    Downing A; Morris EJ; Aravani A; Finan PJ; Lawton S; Thomas JD; Sebag-Montefiore D
    Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):708-12. PubMed ID: 26188917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Relevance of HPV Infection and p16 Overexpression in Squamous Cell Anal Cancer.
    Mai S; Welzel G; Ottstadt M; Lohr F; Severa S; Prigge ES; Wentzensen N; Trunk MJ; Wenz F; von Knebel-Doeberitz M; Reuschenbach M
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):819-27. PubMed ID: 26530750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
    Grabenbauer GG; Kessler H; Matzel KE; Sauer R; Hohenberger W; Schneider IH
    Dis Colon Rectum; 2005 Sep; 48(9):1742-51. PubMed ID: 15991058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
    Seo Y; Kinsella MT; Reynolds HL; Chipman G; Remick SC; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):143-9. PubMed ID: 19203845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of anal cancer patients at the Ottawa hospital.
    Abunassar M; Reinders J; Jonker DJ; Asmis T
    Eur J Surg Oncol; 2015 May; 41(5):653-8. PubMed ID: 25776438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Squamous cell carcinoma of the anal margin: the university of Florida experience.
    Balamucki CJ; Zlotecki RA; Rout WR; Newlin HE; Morris CG; Kirwan JM; George TJ; Mendenhall WM
    Am J Clin Oncol; 2011 Aug; 34(4):406-10. PubMed ID: 20881476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities.
    Edelman S; Johnstone PA
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):206-11. PubMed ID: 16904522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort.
    Bentzen AG; Guren MG; Wanderås EH; Frykholm G; Tveit KM; Wilsgaard T; Dahl O; Balteskard L
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e173-80. PubMed ID: 22436791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Anticancer Res; 2016 Apr; 36(4):2027-32. PubMed ID: 27069197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control.
    Zilli T; Betz M; Bieri S; Ris F; Roche B; Roth AD; Allal AS
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):60-6. PubMed ID: 23608237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
    Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
    Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy.
    Fraunholz I; Weiss C; Eberlein K; Haberl A; Rödel C
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1425-32. PubMed ID: 19744801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?
    Zilli T; Schick U; Ozsahin M; Gervaz P; Roth AD; Allal AS
    Radiother Oncol; 2012 Jan; 102(1):62-7. PubMed ID: 21993403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma.
    Oehler-Jänne C; Seifert B; Lütolf UM; Studer G; Glanzmann C; Ciernik IF
    Brachytherapy; 2007; 6(3):218-26. PubMed ID: 17681244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial.
    Peiffert D; Tournier-Rangeard L; Gérard JP; Lemanski C; François E; Giovannini M; Cvitkovic F; Mirabel X; Bouché O; Luporsi E; Conroy T; Montoto-Grillot C; Mornex F; Lusinchi A; Hannoun-Lévi JM; Seitz JF; Adenis A; Hennequin C; Denis B; Ducreux M
    J Clin Oncol; 2012 Jun; 30(16):1941-8. PubMed ID: 22529257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy.
    Rödel F; Wieland U; Fraunholz I; Kitz J; Rave-Fränk M; Wolff HA; Weiss C; Wirtz R; Balermpas P; Fokas E; Rödel C
    Int J Cancer; 2015 Jan; 136(2):278-88. PubMed ID: 24839133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.